FDA Fosamax Femur Fractures — What the FDA is Telling You About Your Risk of Injury

In 2010, the FDA issued a safety announcement about the use of bisphosphonate osteoporosis drugs such as Fosamax. At that time and based on the information available the FDA found that, "Although it is not clear if bisphosphonates are the cause, these unusual femur fractures have been predominantly reported in patients taking bisphosphonates." According to the FDA, Fosamax femur fractures were a significant enough concern that the agency recommended the Fosamax medication guide be updated to include the risk and that women promptly report any symptoms of a femur fracture to their doctors.

FDA and Fosamax in 2011

In 2011, women gathered to tell their stories to an FDA advisory committee. Fosamax injuries were described and as a result the FDA advisory committee recommended increasing the strength of the warning on Fosamax and other bisphosphonates but it did not recommend limiting the use of the drugs. The FDA typically follows the recommendations of its advisory committees.

The FDA, while stopping short of drawing a clear connection between Fosamax and rare and atypical femur fractures is warning women to be aware of the risk and to consult with their doctors.

Let us review your case:

() -

About Anapol Schwartz

  • Anapol Schwartz is nationally known for the handling of unsafe drug cases. Many pharmaceutical related injuries occur because of failures to warn of side effects, such as the case with Topamax, where clinical trials are not large enough or are too short in duration to determine increased risks. Often, the unknown effects will surface when drugs are prescribed off-label or improperly.

  • If you or someone you know taken unsafe drugs and has been severely injured as a result, our unsafe drug lawyers can assist you in evaluating your case. Click here for a free case evaluation.